Laura Francis Sells 10,048 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CEO Laura Francis sold 10,048 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.58, for a total transaction of $126,403.84. Following the sale, the chief executive officer now directly owns 482,875 shares of the company’s stock, valued at $6,074,567.50. The trade was a 2.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

SI-BONE Trading Up 1.3 %

SIBN opened at $12.31 on Friday. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $21.70. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The stock has a 50-day moving average of $13.79 and a 200 day moving average of $14.23. The firm has a market cap of $516.24 million, a P/E ratio of -13.38 and a beta of 1.22.

Institutional Trading of SI-BONE

Institutional investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in shares of SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after purchasing an additional 1,198 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of SI-BONE during the second quarter valued at approximately $61,000. Walleye Capital LLC purchased a new stake in shares of SI-BONE in the third quarter worth approximately $144,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of SI-BONE by 24.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock worth $138,000 after acquiring an additional 2,108 shares during the last quarter. Finally, Arizona State Retirement System grew its position in SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after acquiring an additional 903 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a report on Wednesday. Morgan Stanley reduced their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, Truist Financial lifted their target price on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.